Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Diakron Pharmaceuticals Inc.

Latest From Diakron Pharmaceuticals Inc.

Orchid and Merck & Co enter R&D collaboration for anti-infectives

Orchid Chemicals and Pharmaceuticalsand Merck & Cohave entered into a R&D collaboration and licence agreement to develop novel agents for bacterial and fungal infections.

India Companies

Orchid invests in Diakron

Orchid Chemicals and Pharmaceuticalshas acquired majority control in Diakron Pharmaceuticals, the US drug development firm that has an exclusive licence for an investigational oral anticoagulant drug candidate discovered and developed through Phase I by Merck & Co. Diakron has the exclusive rights to develop, and, if approved, market and distribute the compound worldwide.

Metabolic Disorders Cardiovascular
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Cardiovascular
  • Metabolic Disorders
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Diakron Pharmaceuticals Inc.
  • Senior Management
  • Martin E Cearnal, CEO
    Srirama Rao, PhD, CSO
  • Contact Info
  • Diakron Pharmaceuticals Inc.
    Phone: (619) 665-3077
    P.O. Box 80
    Morris Plains, NJ 07950